Michaud JE, Billups KL, Partin AW. Testosterone and Prostate Cancer: an Evidence-Based Review of Pathogenesis and Oncologic Risk. Ther Adv Urol [Internet]. 2015;7(6):378–87. Available from: http://dx.doi.org/10.1177/1756287215597633
Wilt, Timothy J; Ishani, Areef; MacDonald, Roderick; Stark, Gerold; Mulrow, Cynthia D; Lau, Joseph (26 de julio de 1999). «Beta-sitosterols for benign prostatic hyperplasia». En Cochrane Urology Group, ed. Cochrane Database of Systematic Reviews(en inglés). doi:10.1002/14651858.CD001043. Consultado el 14 de abril de 2021.
Barry MJ, Fowler FJ Jr, O'Leary MP, et al (1992). The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol148(5): 1549-57. PMID 1279218
Kaplan SA, McConnell JD, Roehrborn CG, et al (2006). Combination therapy with doxazosin and finasteride for benign prostatic
hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol175(1): 217-20. PMID 16406915.
McVary KT, Monnig W, Camps JL Jr, et al (2007). Sildenafil citrate improves erectile function and urinary symptoms in men with
erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol177(3) :1071-7. PMID 17296414
Wilt, Timothy J; Ishani, Areef; MacDonald, Roderick; Stark, Gerold; Mulrow, Cynthia D; Lau, Joseph (26 de julio de 1999). «Beta-sitosterols for benign prostatic hyperplasia». En Cochrane Urology Group, ed. Cochrane Database of Systematic Reviews(en inglés). doi:10.1002/14651858.CD001043. Consultado el 14 de abril de 2021.